Figure 3 from Clinically Relevant Humanized Mouse Models of Metastatic Prostate Cancer Facilitate Therapeutic Evaluation

Activated T-cell immune profile in huNOG tumors. A, Gating strategy employed to determine T-cell activation status. B, Total percentage of CD45+ cells acquired from tumor tissue harvesting split between the intact control, castrated vehicle, and castrated with enzalutamide treatment. C, Percentage of CD3+ cells observed in the total CD45+ population. D, Percentage of CD3+ cells showing IFNγ expression via intracellular staining. E, Measurement of the percentage of CD4+ cells expressing IFNγ harvested from the spleen. F, Measurement of CD8+ cells expressing IFNγ from the spleen. G, Spleen bioluminescent metastasis signal quantification.